Pacific released a research report on April 8, stating that Jiujiang Biotech (300406.SZ) was given a purchase rating. The main reasons for the rating include: 1) full recovery of outpatient and surgical volumes in medical institutions, driving growth in biochemical and pathologic reagent sales; 2) cooperating with EGI to explore overseas and deepen the global layout strategy; 3) Sinopharm's multi-faceted empowerment to vigorously develop the pathology sector; 4) sales expenses dropped significantly, and the overall net margin increased by 3.87 pct. (Mainichi Keizai Shimbun)
太平洋4月8日发布研报称，给予九强生物（300406.SZ）买入评级。评级理由主要包括：1）医疗机构门诊及手术量全面恢复，带动生化及病理试剂销售增长；2）与EGI合作探索出海，深化全球化布局战略；3）国药多方面赋能，大力发展病理板块；4）销售费用率下降明显，整体净利率提升3.87pct。（每日经济新闻）
Pacific released a research report on April 8, stating that Jiujiang Biotech (300406.SZ) was given a purchase rating. The main reasons for the rating include: 1) full recovery of outpatient and surgical volumes in medical institutions, driving growth in b
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.